Table 2 ORs and 95% CIs for cytokine and cytokine-related marker positivity in premorbid and postdiagnostic sera from 49 patients with RA and 245 matched controls
Premorbid seraPostdiagnostic sera
Positivity in RA case sera >5 years before diagnosis* (n = 30)Positivity in RA case sera ⩽5 years before diagnosis* (n = 19)Positivity in postdiagnostic RA case sera* (n = 33)
Percentage (n)OR 95% CIPercentage (n)OR 95% CIPercentage (n)OR† 95% CI
Anti-IL-1α IgG0 (0)0.9 (0.0 to 5.6)5 (1)1.0 (0.0 to 10.0)3 (1)0.8 (0.0 to 6.1)
IL-1α3 (1)0.4 (0.0 to 2.7)11 (2)8.2 (0.9 to ∞)18 (6)4.7 (1.4 to 15.4)
IL-1β0 (0)0.5 (0.0 to 2.7)11 (2)2.1 (0.3 to 12.2)33 (11)11.2 (3.6 to 41.2)
IL-1RA3 (1)0.6 (0.0 to 3.9)11 (2)2.5 (0.3 to 14.1)15 (5)5.2 (1.3 to 22.1)
IL-20 (0)0 –5 (1)1.7 (0.1 to 15.6)30 (10)11.2 (3.6 to 41.6)
IL-47 (2)1.7 (0.2 to 7.9)11 (2)5.0 (0.5 to 48.0)21 (7)7.6 (2.2 to 29.9)
IL-50 (0)0 –0 (0)0 –9 (3)12.4 (1.3 to 335)
IL-63 (1)0.4 (0.0 to 2.8)0 (0)0 –12 (4)1.9 (0.5 to 6.3)
IL-83 (1)0.6 (0.0 to 3.4)0 (0)0 –0 (0)0 –
IL-100 (0)0 –5 (1)2.5 (0.1 to 32.9)18 (6)3.6 (1.1 to 11.3)
IL-12P703 (1)0.5 (0.0 to 3.6)5 (1)1.8 (0.1 to 25.1)21 (7)5.3 (1.6 to 18.6)
TNF-α0 (0)0 –16 (3)12.4 (1.3 to 335)27 (9)13.3 (3.7 to 61.3)
TNF-RI0 (0)0 –5 (1)3.2 (0.1 to 136)48 (16)35.2 (9.2 to 228)
TNF-RII3 (1)0.7 (0.0 to 5.2)5 (1)1.0 (0.0 to 8.3)61 (20)40.4 (10.8 to 258)
Interferon-γ7 (2)1.5 (0.2 to 7.8)5 (1)1.0 (0.0 to 7.2)6 (2)2.5 (0.3 to 14.1)
GM-CSF3 (1)1.3 (0.0 to 12.6)0 (0)0 –3 (1)5.0 (0.1 to 195)
  • RA, rheumatoid arthritis; IL, interleukin; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.

  • When no cases were positive the OR was set to 0.

  • *Cut-off value defining positivity is given as the 95th percentile of control sera when 5% or more had detectable levels. †OR estimated by comparing postdiagnostic measurements in RA cases with premorbid measurements in matched controls.